|Bid||19.05 x 1200|
|Ask||19.89 x 1300|
|Day's Range||19.00 - 19.47|
|52 Week Range||16.10 - 24.57|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.25|
MOUNTAIN VIEW, Calif., Oct. 02, 2019 -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company focused on creating and developing engineered IgM antibodies for the.
MOUNTAIN VIEW, Calif., Sept. 20, 2019 -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the closing of its initial public offering of 12,578,125 shares of its common.
IGM Biosciences (NASDAQ: IGMS ) made its public debut Wednesday morning, opening at $18.31 after being priced at $16 per share. The company's shares are listed on the Nasdaq under the ticker symbol "IGMS." ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) 10X Genomics Inc (NASDAQ: TXG ) (listed ...
MOUNTAIN VIEW, Calif., Sept. 17, 2019 -- IGM Biosciences, Inc. (Nasdaq: IGMS) today announced the pricing of its initial public offering of 10,937,500 shares of its common.
Mountain View, California-based IGM Biosciences, Inc. proposes to offer 10.938 million shares in an IPO at an estimated price range of $15-$17 per share, according to a S-1/A filing. The company's shares have been approved for listing on the Nasdaq under the ticker symbol IGMS. IGM is a biotech company involved in the development of engineering IgM antibodies for the treatment of cancer patients.